HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Scott Lundeen Selected Research

JNJ10258859

7/2003Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Scott Lundeen Research Topics

Disease

2Prostatic Neoplasms (Prostate Cancer)
05/2007 - 01/2007
2Neoplasms (Cancer)
01/2007 - 03/2005
2Erectile Dysfunction
03/2005 - 07/2003
1Wasting Syndrome (Wasting Disease)
06/2008
1Hypogonadism (Hypergonadotropic Hypogonadism)
06/2008
1Osteoporosis
06/2008
1Brain Neoplasms (Brain Tumor)
03/2005

Drug/Important Bio-Agent (IBA)

2Androgen Receptors (Androgen Receptor)IBA
06/2008 - 01/2007
1LigandsIBA
06/2008
1JNJ 37654032IBA
06/2008
1Nonsteroidal Anti-AndrogensIBA
05/2007
1Anabolic AgentsIBA
01/2007
1JNJ-26146900IBA
01/2007
1Phosphodiesterase 5 InhibitorsIBA
03/2005
1Pharmaceutical PreparationsIBA
03/2005
1Estrogens (Estrogen)FDA Link
03/2005
1JNJ10258859IBA
07/2003

Therapy/Procedure

1Orchiectomy (Orchidectomy)
01/2007